Abstract
Current studies have found that allogenic mesenchymal stem cells (MSCs) transplantation (MSCT) can be used successfully in mouse and human SLE. However, syngeneic bone marrow (BM)-MSCT was ineffective. Recently, studies also revealed that BM-MSCs from SLE patients showed senescent behavior. These findings suggested that the senescence of BM-MSCs from SLE patients may be a contributing factor to disease pathogenesis. So further findings about MSCs senescence of SLE will contribute to lay the groundwork for the development of new therapeutic approaches to treat SLE. In this review, we summarize the characteristics of MSCs, molecular mechanisms and signaling involved in MSCs senescence and the senescent biological behavior of MSCs from SLE and possible mechanisms. Analyzing the mechanisms of controlling MSCs senescence may provide a therapeutic target for SLE.
Keywords: DNA damage, immunomodulation, Mesenchymal stem cells (MSCs), molecular mechanisms, senescence, Systemic Lupus Erythematosus (SLE).
Current Signal Transduction Therapy
Title:The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus
Volume: 8 Issue: 2
Author(s): Guijuan Feng, Wei Tan and Zhifeng Gu
Affiliation:
Keywords: DNA damage, immunomodulation, Mesenchymal stem cells (MSCs), molecular mechanisms, senescence, Systemic Lupus Erythematosus (SLE).
Abstract: Current studies have found that allogenic mesenchymal stem cells (MSCs) transplantation (MSCT) can be used successfully in mouse and human SLE. However, syngeneic bone marrow (BM)-MSCT was ineffective. Recently, studies also revealed that BM-MSCs from SLE patients showed senescent behavior. These findings suggested that the senescence of BM-MSCs from SLE patients may be a contributing factor to disease pathogenesis. So further findings about MSCs senescence of SLE will contribute to lay the groundwork for the development of new therapeutic approaches to treat SLE. In this review, we summarize the characteristics of MSCs, molecular mechanisms and signaling involved in MSCs senescence and the senescent biological behavior of MSCs from SLE and possible mechanisms. Analyzing the mechanisms of controlling MSCs senescence may provide a therapeutic target for SLE.
Export Options
About this article
Cite this article as:
Feng Guijuan, Tan Wei and Gu Zhifeng, The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113089990003
DOI https://dx.doi.org/10.2174/15743624113089990003 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Interaction and Reaction of the Antioxidant Mn<sup>III</sup> [Meso-Tetrakis(4-NMethyI Pyridinium) Porphyrin] with the Apoptosis Reporter Lipid Phosphatidylserine
Current Physical Chemistry Psychotherapy Through Video Game to Target Illness Related Problematic Behaviors of Children with Brain Tumor
Current Medical Imaging Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Current Medicinal Chemistry The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy Stability of Genomic Imprinting in Embryonic Stem Cells: Lessons from Assisted Reproductive Technology
Current Stem Cell Research & Therapy The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology